Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

3,968 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
Baines SD, Freeman J, Wilcox MH. Baines SD, et al. Among authors: freeman j. J Antimicrob Chemother. 2005 Jun;55(6):974-82. doi: 10.1093/jac/dki120. Epub 2005 Apr 28. J Antimicrob Chemother. 2005. PMID: 15860551
Antibiotics and Clostridium difficile.
Freeman J, Wilcox MH. Freeman J, et al. Microbes Infect. 1999 Apr;1(5):377-84. doi: 10.1016/s1286-4579(99)80054-9. Microbes Infect. 1999. PMID: 10602670 Review.
In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.
Wilcox MH, Fawley W, Freeman J, Brayson J. Wilcox MH, et al. Among authors: freeman j. J Antimicrob Chemother. 2000 Oct;46(4):551-6. doi: 10.1093/jac/46.4.551. J Antimicrob Chemother. 2000. PMID: 11020251
Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates.
Freeman J, Wilcox MH. Freeman J, et al. J Antimicrob Chemother. 2001 Feb;47(2):244-6. doi: 10.1093/jac/47.2.244. J Antimicrob Chemother. 2001. PMID: 11157920 No abstract available.
Ureidopenicillins and risk of Clostridium difficile infection.
Freeman J, Wilcox MH. Freeman J, et al. J Antimicrob Chemother. 2001 May;47(5):719. doi: 10.1093/oxfordjournals.jac.a002689. J Antimicrob Chemother. 2001. PMID: 11328794 No abstract available.
Faecal concentrations of piperacillin and tazobactam in elderly patients.
Wilcox MH, Brown A, Freeman J. Wilcox MH, et al. Among authors: freeman j. J Antimicrob Chemother. 2001 Jul;48(1):155-6. doi: 10.1093/jac/48.1.155. J Antimicrob Chemother. 2001. PMID: 11418534 No abstract available.
Reduced susceptibility of Clostridium difficile to metronidazole.
Brazier JS, Fawley W, Freeman J, Wilcox MH. Brazier JS, et al. Among authors: freeman j. J Antimicrob Chemother. 2001 Nov;48(5):741-2. doi: 10.1093/jac/48.5.741. J Antimicrob Chemother. 2001. PMID: 11679570 No abstract available.
The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces.
Freeman J, Wilcox MH. Freeman J, et al. J Clin Pathol. 2003 Feb;56(2):126-8. doi: 10.1136/jcp.56.2.126. J Clin Pathol. 2003. PMID: 12560391 Free PMC article.
Evidence to support the existence of subgroups within the UK epidemic Clostridium difficile strain (PCR ribotype 1).
Fawley WN, Freeman J, Wilcox MH. Fawley WN, et al. Among authors: freeman j. J Hosp Infect. 2003 May;54(1):74-7. doi: 10.1016/s0195-6701(03)00079-3. J Hosp Infect. 2003. PMID: 12767851
Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.
Freeman J, O'Neill FJ, Wilcox MH. Freeman J, et al. J Antimicrob Chemother. 2003 Jul;52(1):96-102. doi: 10.1093/jac/dkg267. Epub 2003 May 29. J Antimicrob Chemother. 2003. PMID: 12775682
3,968 results
Jump to page
Feedback